Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Citi
US Department of Justice
Cerilliant
Accenture
Harvard Business School
Queensland Health
Farmers Insurance
Healthtrust
McKinsey

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,295,657

« Back to Dashboard

Which drugs does patent 9,295,657 protect, and when does it expire?

Patent 9,295,657 protects ADRENALIN and is included in two NDAs.

This patent has three patent family members in three countries.
Summary for Patent: 9,295,657
Title:Epinephrine formulations
Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
Inventor(s): Kannan; Vinayagam (Rochester, MI), Irish; Patrick (Sterling Heights, MI), Bergren; Michael (Henderson, NV)
Assignee: Par Pharmaceutical, Inc. (Chestnut Ridge, NY)
Application Number:14/818,121
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,295,657

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Par Sterile Products ADRENALIN epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 204200-001 Dec 7, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS ➤ Try a Free Trial
Par Sterile Products ADRENALIN epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 204640-001 Dec 18, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,295,657

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,119,876 Epinephrine formulations ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,295,657

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2016149028 ➤ Try a Free Trial
Canada 2978464 ➤ Try a Free Trial
Australia 2016233682 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
AstraZeneca
Fish and Richardson
Cerilliant
Moodys
Johnson and Johnson
Farmers Insurance
Cipla
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot